FDA Granted AstaPure
“Astaxanthin is one of the most researched bioactive ingredients, and AstaPure is a leading brand for purity and quality,” says Efrat Kat, Marketing & Sales Director at Algatechnologies. “This important move will help us engender more market-share growth in the US.”
30 Oct 2009 --- Algatechnologies, Israel, announced that the FDA reviewed and is allowing the use of twelve new structural health claims filed for its AstaPure brand of natural astaxanthin in the US market.
For more than ten years, astaxanthin’s role in enhancing the immune system and preventing oxidative stress has been the subject of international research both in universities and commercial enterprises. All health claims approved for the AstaPure brand are based on a vast number of clinical and pre-clinical trials proving the health benefits of natural astaxanthin to human health and wellness.
“Astaxanthin is one of the most researched bioactive ingredients, and AstaPure is a leading brand for purity and quality,” says Efrat Kat, Marketing & Sales Director at Algatechnologies. “This important move will help us engender more market-share growth in the US.”
It is worth noting the major principle behind structural health claims regulation is that all advertising must be truthful and not misleading, and advertisers must have substantiation for all objective advertising claims before the claims are disseminated. The Commission normally requires an advertiser to have competent and reliable scientific evidence.
Among the health claims approved for AstaPure are claims supporting cardiovascular health, neurological health and the advantage of AstaPure in maintaining a normal oxidant/antioxidant balance.
“The growth in sales of astaxanthin in the US is a direct result of the increasing number of new studies on the positive role of astaxanthin in improving human health,” notes Kat. “The allowed use of the health claims are a part of the company's global plan to invest in expanding regulatory approvals for its growing products line. Other countries in which the company has plans to increase its presence are South Korea, India and Australia.
